首页 > 最新文献

BMC Cancer最新文献

英文 中文
Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021. 2002 - 2021年中国居民肝癌死亡率趋势分析
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-07 DOI: 10.1186/s12885-026-15660-9
Yuxin Wang, Miao Lu, Xu Su, Chunying Cui, Wei Zhang, Guoping Wang
{"title":"Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021.","authors":"Yuxin Wang, Miao Lu, Xu Su, Chunying Cui, Wei Zhang, Guoping Wang","doi":"10.1186/s12885-026-15660-9","DOIUrl":"https://doi.org/10.1186/s12885-026-15660-9","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study. 达格列净对乳腺癌合并2型糖尿病患者阿霉素诱导的心脏毒性的心脏保护作用:一项前瞻性研究
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-07 DOI: 10.1186/s12885-026-15696-x
Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul
<p><strong>Aim: </strong>This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.</p><p><strong>Materials and methods: </strong>In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.</p><p><strong>Results: </strong>In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.</p><p><strong>Conclusion: </strong>In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi
{"title":"Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.","authors":"Huseyin Ali Ozturk, Mevlut Koc, Ramazan Azim Okyay, Dilan Damla Ozturk, Erdinc Gulumsek, Mahmut Buyuksimsek, Mehmet Turker, Abdullah Eren Cetin, Fatih Necip Arici, Hilmi Erdem Sumbul","doi":"10.1186/s12885-026-15696-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15696-x","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled. Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group. The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy. N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment. Between-group baseline characteristics were compared using the independent samples t-test for continuous variables. Within-group changes from baseline to 3 months were analyzed with paired t-tests. Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests. To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed. Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated. In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367 [95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p &lt; 0.001). At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133 [95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000 [95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p &lt; 0.001). Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy. The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients. These hypothesis-generating findi","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of surgery plus radiation versus surgery alone in the management for complicated orbital solitary fibrous tumor: a new insight on a rare disease. 手术加放疗与单纯手术在治疗复杂的眼眶孤立性纤维性肿瘤中的作用:对一种罕见疾病的新认识。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-07 DOI: 10.1186/s12885-026-15690-3
Yinan Han, Jiang Qian, Jinwei Cheng, Li Yan
{"title":"The role of surgery plus radiation versus surgery alone in the management for complicated orbital solitary fibrous tumor: a new insight on a rare disease.","authors":"Yinan Han, Jiang Qian, Jinwei Cheng, Li Yan","doi":"10.1186/s12885-026-15690-3","DOIUrl":"https://doi.org/10.1186/s12885-026-15690-3","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lived experience and attitudes of esophageal cancer patients toward stenting-based care at Asella referral hospital: a qualitative exploration from a resource-limited setting in South-Eastern Ethiopia. Asella转诊医院食管癌患者对支架治疗的生活经验和态度:来自埃塞俄比亚东南部资源有限的定性探索。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-07 DOI: 10.1186/s12885-026-15707-x
Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho
{"title":"Lived experience and attitudes of esophageal cancer patients toward stenting-based care at Asella referral hospital: a qualitative exploration from a resource-limited setting in South-Eastern Ethiopia.","authors":"Jibril Bashir Adem, Abebe Megerso Adilo, Haji Aman Deybasso, Muhammed Kabeto, Anas Ali Alhur, Tewodros Desalegn Nebi, Gadisa Dejene, Mengesha Akale Tekle, Jemal Reshad Tarie, Mifta Dellil Hamid, Melik Tiba, Abashamo Lencho","doi":"10.1186/s12885-026-15707-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15707-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review. CDK4/6抑制剂进展后HR+/HER2晚期乳腺癌治疗的疗效和安全性:一项网络荟萃分析和范围审查
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-07 DOI: 10.1186/s12885-026-15632-z
Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong
{"title":"Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.","authors":"Li Zhang, Fan Sun, Xiaorui Wang, Weipeng Zhao, Yongsheng Jia, Haotian Wang, Yuqi Han, Zhongsheng Tong","doi":"10.1186/s12885-026-15632-z","DOIUrl":"https://doi.org/10.1186/s12885-026-15632-z","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients with tumor deposits benefit equally from adjuvant therapy compared to other stage III colon cancer groups: two retrospective population-based studies. 与其他III期结肠癌组相比,肿瘤沉积患者同样受益于辅助治疗:两项基于人群的回顾性研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-06 DOI: 10.1186/s12885-026-15668-1
Ayse Selcen Oguz Erdogan, Yao Shu, Elske Gootjes, Femke Simmer, Iris D Nagtegaal
{"title":"Patients with tumor deposits benefit equally from adjuvant therapy compared to other stage III colon cancer groups: two retrospective population-based studies.","authors":"Ayse Selcen Oguz Erdogan, Yao Shu, Elske Gootjes, Femke Simmer, Iris D Nagtegaal","doi":"10.1186/s12885-026-15668-1","DOIUrl":"https://doi.org/10.1186/s12885-026-15668-1","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive bioinformatics analysis and clinical validation of PPP1R13L in rectal adenocarcinoma. PPP1R13L在直肠腺癌中的综合生物信息学分析及临床验证。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-06 DOI: 10.1186/s12885-026-15663-6
Qian Wang, Yin-Kun Wang, Ping Zhang, Wen-Kang Liu
{"title":"Comprehensive bioinformatics analysis and clinical validation of PPP1R13L in rectal adenocarcinoma.","authors":"Qian Wang, Yin-Kun Wang, Ping Zhang, Wen-Kang Liu","doi":"10.1186/s12885-026-15663-6","DOIUrl":"https://doi.org/10.1186/s12885-026-15663-6","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The diagnostic value of enhanced CT radiomics and deep learning in differentiating pediatric peripheral neuroblastoma from ganglioneuroblastoma. 增强CT放射组学和深度学习在鉴别小儿周围神经母细胞瘤和神经节神经母细胞瘤中的诊断价值。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-06 DOI: 10.1186/s12885-026-15665-4
Guangfeng Zhang, Feng Gao, Lei Fan, Wenbin Guo, Jianshe Zhao
{"title":"The diagnostic value of enhanced CT radiomics and deep learning in differentiating pediatric peripheral neuroblastoma from ganglioneuroblastoma.","authors":"Guangfeng Zhang, Feng Gao, Lei Fan, Wenbin Guo, Jianshe Zhao","doi":"10.1186/s12885-026-15665-4","DOIUrl":"https://doi.org/10.1186/s12885-026-15665-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Missed anal and anorectal tumors during endoscopic examinations: a ten-year retrospective study. 内镜检查中漏诊肛门和肛肠肿瘤:一项十年回顾性研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-06 DOI: 10.1186/s12885-026-15671-6
Zhu-Jun Wu, Hui Gong, Ya-Xin Li, Yuan Li, Wei-Yi Wu, Lin-Jie Guo

Background: The extent to which anal and anorectal tumors are missed during endoscopic examinations has not been thoroughly investigated. This study investigated the clinical features of tumors that were missed during endoscopic examinations.

Aim: To investigate and analyze the endoscopic and clinical features of missed anal and anorectal tumors.

Methods: All patients diagnosed with anal and anorectal tumors between 2014 and 2024 at West China Hospital were included in this retrospective cohort analysis. Demographic data, tumor characteristics, endoscopic findings, and missed diagnosis records were extracted from electronic medical records and telephone follow-up. A descriptive and error-classification analysis was performed to identify the reasons for missed diagnoses during endoscopy.

Results: Descriptive and error-classification analysis among the 83 enrolled patients, 10 (7 with adenocarcinoma and 3 with squamous cell carcinoma) had undergone previous endoscopic examinations with negative diagnoses, resulting in a missed detection proportion of 12.0%. Six missed cases with 15 prior colonoscopies in which the lesions were overlooked had complete medical records. The mean number of endoscopic procedures performed prior to the definitive diagnosis was 2.5 (range: 1-5), with an average diagnostic delay of 43.4 months (range: 1-82). The causes of missed diagnoses included exposure errors (n = 8), judgment errors (n = 6), and biopsy errors (n = 1). The proportion of endoscopic rectal retroflexion to observe anus was 20% .

Conclusion: The missed diagnosis proportion of anal and anorectal tumors was high during endoscopic examination. Comprehensive endoscopic observation and enhanced recognition of the endoscopic features of anal tumors are essential.

{"title":"Missed anal and anorectal tumors during endoscopic examinations: a ten-year retrospective study.","authors":"Zhu-Jun Wu, Hui Gong, Ya-Xin Li, Yuan Li, Wei-Yi Wu, Lin-Jie Guo","doi":"10.1186/s12885-026-15671-6","DOIUrl":"https://doi.org/10.1186/s12885-026-15671-6","url":null,"abstract":"<p><strong>Background: </strong>The extent to which anal and anorectal tumors are missed during endoscopic examinations has not been thoroughly investigated. This study investigated the clinical features of tumors that were missed during endoscopic examinations.</p><p><strong>Aim: </strong>To investigate and analyze the endoscopic and clinical features of missed anal and anorectal tumors.</p><p><strong>Methods: </strong>All patients diagnosed with anal and anorectal tumors between 2014 and 2024 at West China Hospital were included in this retrospective cohort analysis. Demographic data, tumor characteristics, endoscopic findings, and missed diagnosis records were extracted from electronic medical records and telephone follow-up. A descriptive and error-classification analysis was performed to identify the reasons for missed diagnoses during endoscopy.</p><p><strong>Results: </strong>Descriptive and error-classification analysis among the 83 enrolled patients, 10 (7 with adenocarcinoma and 3 with squamous cell carcinoma) had undergone previous endoscopic examinations with negative diagnoses, resulting in a missed detection proportion of 12.0%. Six missed cases with 15 prior colonoscopies in which the lesions were overlooked had complete medical records. The mean number of endoscopic procedures performed prior to the definitive diagnosis was 2.5 (range: 1-5), with an average diagnostic delay of 43.4 months (range: 1-82). The causes of missed diagnoses included exposure errors (n = 8), judgment errors (n = 6), and biopsy errors (n = 1). The proportion of endoscopic rectal retroflexion to observe anus was 20% .</p><p><strong>Conclusion: </strong>The missed diagnosis proportion of anal and anorectal tumors was high during endoscopic examination. Comprehensive endoscopic observation and enhanced recognition of the endoscopic features of anal tumors are essential.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation. 结合细胞重编程和质谱法鉴定重编程膀胱癌细胞的蛋白质组学变异:寻找正常化的线索。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2026-02-06 DOI: 10.1186/s12885-026-15634-x
Banu Iskender, Mehmet Sarihan, Bengi Su Rumeysa Barlak, Gurler Akpinar, Murat Kasap
{"title":"Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.","authors":"Banu Iskender, Mehmet Sarihan, Bengi Su Rumeysa Barlak, Gurler Akpinar, Murat Kasap","doi":"10.1186/s12885-026-15634-x","DOIUrl":"https://doi.org/10.1186/s12885-026-15634-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1